In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.
In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.
First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found.
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence.